STOCKHOLDERS’ EQUITY (Tables)

9 Months Ended

Sep. 30, 2025

SCHEDULE OF COMMON STOCK ISSUED AND OUTSTANDING

Issuances in the period January 1 and September 30, 2024

Date		# Shares			Amount			Price/Share		Type	Notice
1/01/2024			—		$	—		$	—
8/19/2024	g		19,221,026			4,139,126			0.215	stock conversion	affiliates
8/19/2024	d		8,973,405			160,950			0.018	warrant exercise	affiliates
8/19/2024	c		776,817			353,840			0.455	debt conversion	affiliates
8/28/2024	g		22,370			14,820			0.662	stock conversion	affiliates
8/28/2024	g		(100,000	)		(500	)		0.005	stock conversion	affiliates
9/30/2024			28,893,618		$	4,668,236		$	0.162

Issuances in the period January 1 and September 30, 2025

Date		# Shares			Amount			Price/Share		Type	Notice
1/01/2025			43,158,248		$	4,407,172		$	0.102
1/10/2025	h		(150,000	)		(750	)		0.005	stock conversion	affiliates
3/31/2025			—			214,780			—	payroll forfeiture*	affiliates
See Note 11	d		421,391			153,342			0.364	2021 Stock Plan	affiliates
9/30/2025			43,429,639		$	4,774,544		$	0.110

*	The transaction originating from the Company’s Officers forfeiting payroll of $941,890, whereof $214,780 was accrued in prior year. (See note 7 for more details).

Common stock

Number of shares of Common Stock issued and outstanding during the reporting period(s):

Issuances in the period January 1 and September 30, 2024

Date		# Shares			Amount			Price/Share		Type	Notice
1/01/2024			144,642,333		$	13,275,356		$	0.089
1/17/2024	a		—			(45,000	)		—	subscription
1/17/2024	a		333,333			45,000			0.135	private placement
1/18/2024	c		3,703,704			371,108			0.100	debt conversion
1/18/2024	c		3,599,289			485,904			0.135	debt conversion	affiliates
1/22/2024	c		4,356,778			—			—	warrant exercise	cashless
1/22/2024	b		8,950,474			1,163,562			0.130	convertible note
3/20/2024	b		906,618			100,000			0.110	convertible note
3/27/2024	c		3,705,808			279,051			0.075	debt conversion
4/04/2024	c		1,000,000			104,000			0.104	debt conversion
4/15/2024	c		479,192			62,295			0.130	convertible note
4/15/2024	a		173,077			18,000			0.104	private placement
4/19/2024	c		250,000			32,125			0.129	debt conversion
4/22/2024	a		194,553			25,000			0.128	private placement
5/16/2024	b		769,231			100,000			0.130	convertible note
5/20/2024	c		1,027,397			150,000			0.146	debt conversion
6/27/2024	a		212,766			20,000			0.094	private placement
8/19/2024	g		(96,105,125	)		(4,139,126	)		0.043	stock conversion	affiliates
8/28/2024	g		(111,847	)		(14,820	)		0.133	stock conversion	affiliates
8/28/2024	g		500,000			500			0.001	stock conversion	affiliates
see Note 11	d		1,886,944			207,289			0.110	2021 Stock Plan	affiliates
see Note 11	d		1,764,123			187,607			0.106	2021 Stock Plan
9/30/2024			82,238,648		$	12,427,851		$	0.151

Issuances in the period January 1 and September 30, 2025

Date		# Shares		Amount		Price/Share		Type	Notice
1/01/2025			86,782,908	$	12,722,039	$	0.147
1/10/2025	d		750,000		750		0.001	stock conversion
9/30/2025	d		—		13,353		—	subscription
see Note 11	d		1,459,335		106,754		0.073	2021 Stock Plan
9/30/2025			88,992,243	$	12,842,896	$	0.144

a	The Company claims an exemption from the registration requirements of the Securities Act for the private placement of these securities pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.
b	The Common Stock underlying the Convertible Note(s) are currently eligible for resale under Rule 144. At the time of sale of the promissory note, the Company claimed an exemption from the registration requirements of the Securities Act for these securities pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.
c	The Company claims an exemption from the registration requirements of the Securities Act pursuant to the Exchange Exemption in Rule 3(a)(9) of the Securities Act.
d	The Company claims an exemption from the registration requirements of the Securities Act for the Compensatory Benefit Plan pursuant to Rule 701 of the Securities Act.
e	The Company claims an exemption from the registration requirements of the Securities Act pursuant to the Exchange Exemption in section 12(a) of the Securities Act.
f	The shares were issued after the Company filed a registration statement with the SEC, on Form S-1
g	The Company claims an exemption from the registration requirements of the Securities Act pursuant to the Exchange Exemption under Rule 145 of the Securities Act.
h	The Company claims an exemption from the registration requirements of the Securities Act pursuant to the Exchange Exemption under Rule 144 of the Securities Act.

Shares approved for conversion, but not yet issued, as per Finder Agreement dated 07/10/2025

Date		# Shares		Amount		Price/Share		Type	Notice
7/10/2025	c		167,000		11,273		0.068	debt conversion
8/10/2025	c		75,000		4,500		0.060	debt conversion
9/10/2025	c		75,000		3,943		0.053	debt conversion
9/30/2025	c		50,000		2,625		0.053	debt conversion
9/30/2025			367,000	$	22,341	$	0.061

SCHEDULE OF STOCK WARRANTS VALUATION ASSUMPTIONS

The fair value of stock warrants granted for the nine months ended September 30, 2025, and December 31, 2024 was calculated with the following assumptions:

	September 30, 2025			December 31, 2024
Risk-free interest rate		3.72 – 4.61	%		3.41 – 4.72	%
Expected dividend yield		0	%		0	%
Volatility factor (monthly)		124.79	%		129.14	%
Expected life of warrant		5 years			5 years

SCHEDULE OF WARRANT ACTIVITY

The following table summarizes the Company’s Common Stock warrant activity for the nine months ended September 30, 2025, and 2024:

SCHEDULE OF WARRANT ACTIVITY

	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Expected Term
Outstanding as at January 1, 2024		1,342,030	$	0.29		3.8
Granted		—		—		—
Exercised		—		—		—
Forfeited/Cancelled		—		—		—
Outstanding as at September 30, 2024		1,342,030	$	0.29		3.2

Outstanding as at January 1, 2025		1,292,030	$	0.22		2.6
Granted		—		—		—
Exercised		—		—		—
Forfeited/Cancelled		—		—		—
Outstanding as at September 30, 2025		1,292,030	$	0.22		2.2

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE WARRANTS

The following table summarizes information about stock warrants that are vested or expected to vest at September 30, 2025, with a market price of $0.071 at September 30, 2025:

Warrants Outstanding and Exercisable

Exercise Price		Number of Warrants		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
$	0.20-0.25		1,264,030	$	0.23		2.2	$	—
	0.47		28,000		0.47		1.9		—
$	0.20-0.47		1,292,030	$	0.22		2.2	$	—

BIOXYTRAN, INC 10-Q